BRAF and neoplasm: In addition, in PTC, the BRAF mutation is intimately associated with extra-thyroidean extension, lymph node metastasis and advanced tumor stages (19,20), which are the main clinicopathological risk factors conventionally associated with the increase of recurrence and mortality rates for thyroid cancer (21).